Open Access iconOpen Access

ARTICLE

crossmark

Apatinib reduces liver cancer cell multidrug resistance by modulating NF-κB signaling pathway

XIAOXIAO HE1, XUEQING ZHOU2, JINPENG ZHANG2, MINGFEI ZHANG2, DANHONG ZENG2, HENG ZHANG1, SHUCAI YANG2,*

1 Department of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
2 Department of Clinical Laboratory, Pingshan Hospital, Southern Medical University (Pingshan District People’s Hospital of Shenzhen), Shenzhen, 518118, China

* Corresponding Author: SHUCAI YANG. Email: email

BIOCELL 2024, 48(9), 1331-1341. https://doi.org/10.32604/biocell.2024.052625

Abstract

Objectives: This investigation aimed to elucidate the inhibitory impact of apatinib on the multidrug resistance of liver cancer both in vivo and in vitro. Methods: To establish a Hep3B/5-Fu resistant cell line, 5-Fu concentrations were gradually increased in the culture media. Hep3B/5-Fu cells drug resistance and its alleviation by apatinib were confirmed via flow cytometry and Cell Counting Kit 8 (CCK8) test. Further, Nuclear factor kappa B (NF-κB) siRNA was transfected into Hep3B/5-Fu cells to assess alterations in the expression of multidrug resistance (MDR)-related genes and proteins. Nude mice were injected with Hep3B/5-Fu cells to establish subcutaneous xenograft tumors and then categorized into 8 treatment groups. The treatments included oxaliplatin, 5-Fu, and apatinib. In the tumor tissues, the expression of MDR-related genes was elucidated via qRT-PCR, immunohistochemistry, and Western blot analyses. Results: The apatinib-treated mice indicated slower tumor growth with smaller size compared to the control group. Both the in vivo and in vitro investigations revealed that the apatinib-treated groups had reduced expression of MDR genes GST-pi, LRP, MDR1, and p-p65. Conclusions: Apatinib effectively suppresses MDR in human hepatic cancer cells by modulating the expression of genes related to MDR, potentially by suppressing the NF-κB signaling pathway.

Keywords


Cite This Article

APA Style
HE, X., ZHOU, X., ZHANG, J., ZHANG, M., ZENG, D. et al. (2024). Apatinib reduces liver cancer cell multidrug resistance by modulating NF-κB signaling pathway. BIOCELL, 48(9), 1331-1341. https://doi.org/10.32604/biocell.2024.052625
Vancouver Style
HE X, ZHOU X, ZHANG J, ZHANG M, ZENG D, ZHANG H, et al. Apatinib reduces liver cancer cell multidrug resistance by modulating NF-κB signaling pathway. BIOCELL . 2024;48(9):1331-1341 https://doi.org/10.32604/biocell.2024.052625
IEEE Style
X. HE et al., “Apatinib reduces liver cancer cell multidrug resistance by modulating NF-κB signaling pathway,” BIOCELL , vol. 48, no. 9, pp. 1331-1341, 2024. https://doi.org/10.32604/biocell.2024.052625



cc Copyright © 2024 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 841

    View

  • 243

    Download

  • 0

    Like

Share Link